Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third dose of BBIBP-Corv in elderly with chronic bronchitis and COPD
NCT05104216Phase 4Unknown
- Sponsor
- China National Biotec Group
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19), sponsored by China National Biotec Group. Primary endpoints: Seroconversion rate and Neutralizing antibody level. Status: unknown.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05104216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104216.